AABB is the voice of the blood and cellular therapies community before the Food and Drug Administration and FDA advisory committees, such as the Blood Products Advisory Committee and Cellular, Tissue, and Gene Therapies Advisory Committee. The Association engages stakeholders within AABB's membership and the broader community to develop materials that provide FDA with the community’s position on draft guidances, proposed regulations and policies, and research priorities. These AABB-led efforts create an important dialogue with federal regulators that helps promote a strong and safe supply of blood and cells.
FDA Publishes Notice on Agency Reorganization
August 05, 2026
Questions for ‘Ask the FDA and CMS/CLIA’ Session at AABB2026 Due Friday
August 04, 2026
REGULATORY UPDATE: FDA Licenses First Freeze-Dried Plasma Product
July 29, 2026
4550 Montgomery Avenue
Suite 700, North Tower
Bethesda, MD 20814
301.907.6977
